Munich- and Boston-based private equity firm TVM Capital has regrouped its life science investment practice by separating operations into two specialist teams: a life science-focused venture capital arm and healthcare private equity division.
The new healthcare private equity team invests growth capital and provides buy-out financing for growth-orientated small- and medium-sized enterprises (SMEs) of the pharmaceutical, diagnostic, medtech and healthcare services industries. In conjunction with the new formation, the team has added Bernie Schuler, formerly a partner and head of healthcare at 3i in Frankfurt, where he built and led the European-dedicated healthcare team.
The life science venture team, headed by Hubert Birner and Alexandra Goll, will continue it multi-stage approach, spanning discovery and development-stage companies with a range of products, technology platforms, single drug development projects as well as investments in market-ready products in the pharmaceutical and medtech markets.
Helmut Schühsler, managing partner of TVM, said, "By building dedicated teams we can offer the best possible support as a financial and strategic partner to young science and technology driven companies as well as entrepreneurial, often family-owned mature companies in the healthcare industry."
TVM has €860m under management.
Copyright © 2010 AltAssets
Article is in the following categories:
Private Equity News» By News Type» Firm News
Private Equity News» By PE Sector» Venture/Growth
Private Equity News» By PE Sector» Buy-out
Private Equity News» By Region» Europe» Western Europe» Germany
Private Equity News» By Region» North America» United States
Private Equity News» By News Type» Firm News
Private Equity News» By PE Sector» Venture/Growth
Private Equity News» By PE Sector» Buy-out
Private Equity News» By Region» Europe» Western Europe» Germany
Private Equity News» By Region» North America» United States








TVM Capital regroups with two specialist teams